Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 09 Mar 2018 Status changed from not yet recruiting to recruiting.
- 07 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.